The acquisition marks a significant shift for Steris, which aims to integrate Xodus Medical’s specialized surgical offerings into its existing infrastructure. This consolidation effort helped drive positive momentum across the sector as traders reacted to the premium valuation placed on niche medical products.

Conversely, Bristol Myers Squibb faced a sharp reversal. Despite reporting progress in a major cancer-drug trial, the company’s share price dipped following the release of mixed data from a late-stage study focused on a lung-condition treatment. The market’s reaction underscores a cautious environment where clinical uncertainty continues to outweigh incremental gains in pharmaceutical pipelines.